ReviewCurrent treatment options in rheumatology2017
Avoidance of Harm From Treatment for ANCA-Associated Vasculitis.
Review in Current treatment options in rheumatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Position statement of the Brazilian society of Rheumatology on mesna use as a preventive therapy for bladder disease in patients with systemic autoimmune diseases and systemic vasculitis under cyclophosphamide treatment.Advances in rheumatology (London, England) · 2024Guideline
- Understanding the burden of ANCA-associated vasculitis.Rheumatology (Oxford, England) · 2026Review
- Review
- Efficacy and safety of avacopan in the treatment of ANCA-associated vasculitis: a systematic review and meta-analysis.BMC rheumatology · 2025Article
- Rituximab in pathologically confirmed sarcoidosis affecting the central nervous system: a multi-center retrospective study.Journal of neurology · 2025Article
- Safety of Avacopan for the Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Combined Data From Three Clinical Trials.ACR open rheumatology · 2025Article
- Efficacy and Safety of Rituximab in Antiglomerular Basement Membrane Disease.Kidney international reports · 2025Article
- Assessment of cardiovascular risk in patients with ANCA-associated vasculitis: A systematic review and meta-analysis.International journal of cardiology. Cardiovascular risk and prevention · 2024Review
- Invasive fungal infection in ANCA-associated vasculitis: Between the Devil and Deep blue sea. Case series and review of the literature.Clinical rheumatology · 2024Review
- Serum levels of fetuin-A as a novel biomarker for disease activity in patients with Takayasu arteritis and granulomatous polyangiitis.Clinical rheumatology · 2022Article
- The frequency of Treg subsets distinguishes disease activity in ANCA vasculitis.Clinical & translational immunology · 2022Article
- The Complement System and ANCA Associated Vasculitis in the Era of Anti-Complement Drugs.Frontiers in immunology · 2022Review
- Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications.Arthritis care & research · 2021Article
- FRAX scores are increased in patients with ANCA-associated vasculitis.International urology and nephrology · 2021Article
- Granulomatous Polyangiitis With Renal Involvement: A Case Report and Review of Literature.Cureus · 2021Article
- Emerging Cellular Therapies for Anti-myeloperoxidase Vasculitis and Other Autoimmune Diseases.Frontiers in immunology · 2021Review
- Crescentic Glomerulonephritis: Pathogenesis and Therapeutic Potential of Human Amniotic Stem Cells.Frontiers in physiology · 2021Review
- Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.ACR open rheumatology · 2020Article
- Targeting IgG Autoantibodies for Improved Cytotoxicity of Bactericidal Permeability Increasing Protein in Cystic Fibrosis.Frontiers in pharmacology · 2020Article
- Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.